Indication: 1. Primary hypercholesterolemia and mixed hyperlipidemia, to reduce elevated TC, LDL-C, ApoB and TG levels. 2. Patients with hypercholesterolemia and risk of atherosclerosis.

Indication: 1. Hypercholesterolemia Patients with primary hypercholesterolemia, including familial hypercholesterolemia (heterozygous type) or mixed hyperlipidemia (equivalent to type IIa and IIb of Fredrickson classification), can use this product to treat elevated total cholesterol, elevated low-density lipoprotein cholesterol, elevated apolipoprotein B and elevated triglycerides if dietary therapy and other non-drug treatments are unsatisfactory. In patients with homozygous familial hypercholesterolemia, atorvastatin calcium can be used in combination with other lipid-lowering therapies (such as LDL plasma dialysis) or alone (when no other treatment is available) to lower total cholesterol and low-density lipoprotein cholesterol. 2. Coronary heart disease Coronary heart disease or coronary heart disease-related critical illnesses (such as diabetes, symptomatic atherosclerotic disease, etc.) combined with high

Indication: Used to treat hypercholesterolemia and mixed hyperlipidemia; prevent and treat coronary heart disease and cerebral stroke.

Indication: This drug can treat elevated total cholesterol, elevated low-density lipoprotein cholesterol, elevated apolipoprotein B and elevated triglycerides. Patients with primary hypercholesterolemia, including familial hypercholesterolemia (heterozygous type) or mixed hyperlipidemia (equivalent to type IIa and IIb of Fredrickson classification), can use this product if the effects of diet therapy and other non-drug treatments are unsatisfactory. In patients with homozygous familial hypercholesterolemia, atorvastatin calcium can be used in combination with other lipid-lowering therapies or alone (when no other treatments are available) to lower total cholesterol and low-density lipoprotein cholesterol. It is mainly suitable for the treatment of hypercholesterolemia and mixed hyperlipidemia; prevention and treatment of coronary heart disease and cerebral stroke.

Indication: This drug can treat elevated total cholesterol, elevated low-density lipoprotein cholesterol, elevated apolipoprotein B and elevated triglycerides. Patients with primary hypercholesterolemia, including familial hypercholesterolemia (heterozygous type) or mixed hyperlipidemia (equivalent to type IIa and IIb of Fredrickson classification), can use this product if the effects of diet therapy and other non-drug treatments are unsatisfactory. In patients with homozygous familial hypercholesterolemia, atorvastatin calcium can be used in combination with other lipid-lowering therapies or alone (when no other treatments are available) to lower total cholesterol and low-density lipoprotein cholesterol. It is mainly suitable for the treatment of hypercholesterolemia and mixed hyperlipidemia; prevention and treatment of coronary heart disease and cerebral stroke.

Indication: This drug can treat elevated total cholesterol, elevated low-density lipoprotein cholesterol, elevated apolipoprotein B and elevated triglycerides. Patients with primary hypercholesterolemia, including familial hypercholesterolemia (heterozygous type) or mixed hyperlipidemia (equivalent to type IIa and IIb of Fredrickson classification), can use this product if the effects of diet therapy and other non-drug treatments are unsatisfactory. In patients with homozygous familial hypercholesterolemia, atorvastatin calcium can be used in combination with other lipid-lowering therapies or alone (when no other treatments are available) to lower total cholesterol and low-density lipoprotein cholesterol. It is mainly suitable for the treatment of hypercholesterolemia and mixed hyperlipidemia; prevention and treatment of coronary heart disease and cerebral stroke.

Indication: This drug can treat elevated total cholesterol, elevated low-density lipoprotein cholesterol, elevated apolipoprotein B and elevated triglycerides. Patients with primary hypercholesterolemia, including familial hypercholesterolemia (heterozygous type) or mixed hyperlipidemia (equivalent to type IIa and IIb of Fredrickson classification), can use this product if the effects of diet therapy and other non-drug treatments are unsatisfactory. In patients with homozygous familial hypercholesterolemia, atorvastatin calcium can be used in combination with other lipid-lowering therapies or alone (when no other treatments are available) to lower total cholesterol and low-density lipoprotein cholesterol. It is mainly suitable for the treatment of hypercholesterolemia and mixed hyperlipidemia; prevention and treatment of coronary heart disease and cerebral stroke.

Indication: 1. Hyperlipidemia (1) For patients with primary hypercholesterolemia, heterozygous familial hypercholesterolemia or mixed hypercholesterolemia, when dietary control and other non-drug treatments are not ideal, simvastatin can be used to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B and triglycerides. Simvastatin also increases high-density lipoprotein cholesterol, thereby reducing the ratio of low-density lipoprotein/high-density lipoprotein and total cholesterol/high-density lipoprotein. (2) For patients with homozygous familial hypercholesterolemia, when dietary control and non-dietary treatments are not ideal, simvastatin can be used to reduce elevated total cholesterol, low-density lipoprotein cholesterol and apolipoprotein B. 2. Coronary heart disease. (1) Reduce the risk of death. (2) Reduce the risk of death from coronary heart disease and non-fatal myocardial infarction. (3) Reduce the risk of stroke and transient ischemic attack. (4) Reduce the risk of myocardial revascularization surgery (coronary artery bypass grafting and percutaneous balloon coronary angioplasty). (5) Delay the progression of atherosclerosis, including the occurrence of new lesions and complete blockage.

Indication: 1. Hyperlipidemia (1) For patients with primary hypercholesterolemia, heterozygous familial hypercholesterolemia or mixed hypercholesterolemia, when dietary control and other non-drug treatments are not ideal, simvastatin can be used to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B and triglycerides. Simvastatin also increases high-density lipoprotein cholesterol, thereby reducing the ratio of low-density lipoprotein/high-density lipoprotein and total cholesterol/high-density lipoprotein. (2) For patients with homozygous familial hypercholesterolemia, when dietary control and non-dietary treatments are not ideal, simvastatin can be used to reduce elevated total cholesterol, low-density lipoprotein cholesterol and apolipoprotein B. 2. Coronary heart disease. (1) Reduce the risk of death. (2) Reduce the risk of death from coronary heart disease and non-fatal myocardial infarction. (3) Reduce the risk of stroke and transient ischemic attack. (4) Reduce the risk of myocardial revascularization surgery (coronary artery bypass grafting and percutaneous balloon coronary angioplasty). (5) Delay the progression of atherosclerosis, including the occurrence of new lesions and complete blockage.

Indication: 1. Hyperlipidemia (1) For patients with primary hypercholesterolemia, heterozygous familial hypercholesterolemia or mixed hypercholesterolemia, when dietary control and other non-drug treatments are not ideal, simvastatin can be used to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B and triglycerides. Simvastatin also increases high-density lipoprotein cholesterol, thereby reducing the ratio of low-density lipoprotein/high-density lipoprotein and total cholesterol/high-density lipoprotein. (2) For patients with homozygous familial hypercholesterolemia, when dietary control and non-dietary treatments are not ideal, simvastatin can be used to reduce elevated total cholesterol, low-density lipoprotein cholesterol and apolipoprotein B. 2. Coronary heart disease. (1) Reduce the risk of death. (2) Reduce the risk of death from coronary heart disease and non-fatal myocardial infarction. (3) Reduce the risk of stroke and transient ischemic attack. (4) Reduce the risk of myocardial revascularization surgery (coronary artery bypass grafting and percutaneous balloon coronary angioplasty). (5) Delay the progression of atherosclerosis, including the occurrence of new lesions and complete blockage.